CompletedNot Applicable

Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas

United States20 participantsStarted 2012-07-13

Plain-language summary

The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must be at least 18 years of age.
✓. Patients must have histologically confirmed new diagnosed high grade glioma by pathology (WHO grade III and IV).
✓. Patients proposed post-operative treatment plan must include standard radiation and temozolomide.
✓. Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others).
✓. Patients must be able to provide written informed consent.
✓. Steroid use is allowed.

What they're measuring

Changes in T Cell subtypes and cytokines as a function of treatment

Timeframe: 6 time points in pts undergoing standard RT/TMZ and adjuvant TMZ

Trial details

NCT IDNCT02041611

SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-09-02

View on ClinicalTrials.gov More High Grade Glioma trials